{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T03:57:14Z","timestamp":1768363034312,"version":"3.49.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,10]]},"abstract":"<jats:p>Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease. In recent years, biologic agents have provided new treatment options for SLE. This study aims to conduct a comparative analysis of the adverse drug events (AEs) associated with anifrolumab (Saphnelo) and belimumab (Benlysta). AEs were extracted from the FDA adverse event reporting system (FAERS) for the period from April 2011 to April 2024. A total of 21,631 cases were collected from the FAERS system (20,819 for belimumab, 812 for anifrolumab). In terms of injury, poisoning, and procedural complications, anifrolumab was more prone to infusion-related reactions (ROR 6.64), while belimumab exhibited unique AEs such as product dose omissions (ROR 12.63), improper device usage techniques (ROR 20.66), and exposure via skin contact (ROR 80.18). In the category of infections and infestations, anifrolumab was more likely to cause herpes zoster (ROR 21.91), whereas belimumab was more commonly associated with influenza (ROR 2.75). Regarding nervous system disorders, anifrolumab showed a higher incidence of headache (ROR 2.83). In skin and subcutaneous tissue disorders, anifrolumab demonstrated strong signals for rash (ROR 2.29). More severely, anifrolumab was associated with a higher risk of pericarditis (ROR 7.92). Additionally, anifrolumab may lead to psychiatric, vascular, renal, and urinary disorders, primarily presenting as confusional state (ROR 2.14), flushing (ROR 2.94), and proteinuria (ROR 10.96). The adverse reactions associated with belimumab are primarily linked to operational factors (such as product dose omissions) and injection site issues (e.g., injection site pain and hemorrhage). AE reports for anifrolumab demonstrated significant complexity and diversity. Enhanced patient monitoring and therapy optimization are urgently required to ensure more effective management of SLE while minimizing risks.<\/jats:p>","DOI":"10.1097\/md.0000000000044960","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:01:08Z","timestamp":1760331668000},"page":"e44960","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparing adverse events of Saphnelo and Benlysta: A real-world observational study based on the FDA adverse event reporting system (FAERS) following STROBE guidelines"],"prefix":"10.1097","volume":"104","author":[{"given":"Ningning","family":"Ren","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingsong","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong Medical University, Jinan, Shandong Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6997-395X","authenticated-orcid":false,"given":"Lin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong Medical University, Jinan, Shandong Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260113","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus.","volume":"403","author":"Hoi","year":"2024","journal-title":"Lancet"},{"key":"R2-20260113","doi-asserted-by":"crossref","first-page":"e073980","DOI":"10.1136\/bmj-2022-073980","article-title":"Advances in the management of systemic lupus erythematosus.","volume":"383","author":"Morand","year":"2023","journal-title":"BMJ"},{"key":"R3-20260113","doi-asserted-by":"crossref","first-page":"ITC81","DOI":"10.7326\/AITC202006020","article-title":"Systemic lupus erythematosus.","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann Intern Med"},{"key":"R4-20260113","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus.","volume":"17","author":"Barber","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"R5-20260113","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.41632","article-title":"Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the centers for disease control and prevention national lupus registries.","volume":"73","author":"Izmirly","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R6-20260113","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: a review.","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"key":"R7-20260113","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus.","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"R8-20260113","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R9-20260113","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","article-title":"Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial.","volume":"79","author":"Brunner","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R10-20260113","doi-asserted-by":"crossref","first-page":"177","DOI":"10.18773\/austprescr.2022.059","article-title":"Anifrolumab for systemic lupus erythematosus.","volume":"45","year":"2022","journal-title":"Aust Prescr"},{"key":"R11-20260113","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.autrev.2017.04.011","article-title":"International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus.","volume":"16","author":"Kleinmann","year":"2017","journal-title":"Autoimmun Rev"},{"key":"R12-20260113","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: a review in systemic lupus erythematosus.","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"R13-20260113","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1136\/ard-2023-225445","article-title":"Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.","volume":"83","author":"Baker","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R14-20260113","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis.","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"R15-20260113","doi-asserted-by":"crossref","first-page":"1225919","DOI":"10.3389\/fphar.2023.1225919","article-title":"Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS).","volume":"14","author":"Su","year":"2023","journal-title":"Front Pharmacol"},{"key":"R16-20260113","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation.","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"R17-20260113","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads.","volume":"36","author":"Masters","year":"2018","journal-title":"Invest New Drugs"},{"key":"R18-20260113","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/14740338.2023.2204228","article-title":"High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive\/mutated malignancies: a pharmacovigilance study based on the FAERS database.","volume":"22","author":"Ma","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"R19-20260113","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1097\/RHU.0000000000002216","article-title":"Disease safety, immunogenicity, and efficacy of recombinant herpes zoster vaccine (RZV or Shingrix) in autoimmune rheumatic diseases: launching a randomized phase 4 study.","volume":"31","author":"Kupa","year":"2025","journal-title":"J Clin Rheumatol"},{"key":"R20-20260113","first-page":"CD003774","article-title":"Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.","volume":"5","author":"Vernooij","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"R21-20260113","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10238-025-01640-z","article-title":"Evaluation of the efficacy and safety of belimumab and telitacicept in patients with systemic lupus erythematosus: results from a retrospective, observational study.","volume":"25","author":"Feng","year":"2025","journal-title":"Clin Exp Med"},{"key":"R22-20260113","doi-asserted-by":"crossref","first-page":"105882","DOI":"10.1016\/j.jbspin.2025.105882","article-title":"Comparative efficacy and safety of anifrolumab for belimumab-experienced and biologic-na\u00efve patients with systemic lupus erythematosus: results from the kyushu collagen disease network for systemic lupus erythematosus (KCDN-SLE) registry.","volume":"92","author":"Ayano","year":"2025","journal-title":"Joint Bone Spine"},{"key":"R23-20260113","doi-asserted-by":"crossref","first-page":"e001424","DOI":"10.1136\/lupus-2024-001424","article-title":"Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report.","volume":"12","author":"van Schaik","year":"2025","journal-title":"Lupus Sci Med"},{"key":"R24-20260113","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1111\/jdv.20616","article-title":"Efficacy and safety profile of anifrolumab in skin lesions of systemic lupus erythematosus.","volume":"39","author":"Kanbar","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R25-20260113","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41392-025-02168-0","article-title":"Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics.","volume":"10","author":"Dai","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"R26-20260113","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.3389\/fimmu.2018.02285","article-title":"BAFF and BAFF-receptor in B cell selection and survival.","volume":"9","author":"Smulski","year":"2018","journal-title":"Front Immunol"},{"key":"R27-20260113","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nri.2017.24","article-title":"Altered B cell signalling in autoimmunity.","volume":"17","author":"Rawlings","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"R28-20260113","doi-asserted-by":"crossref","first-page":"102736","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE).","volume":"20","author":"M\u00f6ckel","year":"2021","journal-title":"Autoimmun Rev"},{"key":"R29-20260113","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.clinthera.2016.02.022","article-title":"Efficacy and safety of belimumab plus standard therapy in patients with systemic lupus erythematosus: a meta-analysis.","volume":"38","author":"Wei","year":"2016","journal-title":"Clin Ther"},{"key":"R30-20260113","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/mr\/roab125","article-title":"Long-term safety and efficacy of belimumab in Japanese patients with SLE: a 7-year open-label continuation study.","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"R31-20260113","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41564-019-0421-x","article-title":"Decoding type I and III interferon signalling during viral infection.","volume":"4","author":"Mesev","year":"2019","journal-title":"Nat Microbiol"},{"key":"R32-20260113","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.1074\/jbc.R116.774562","article-title":"The molecular basis for differential type I interferon signaling.","volume":"292","author":"Schreiber","year":"2017","journal-title":"J Biol Chem"},{"key":"R33-20260113","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/annrheumdis-2021-221425","article-title":"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.","volume":"81","author":"Vital","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R34-20260113","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R35-20260113","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/art.41598","article-title":"Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase II open-label extension study.","volume":"73","author":"Chatham","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R36-20260113","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/09612033231153536","article-title":"Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab?","volume":"32","author":"Breillat","year":"2023","journal-title":"Lupus"},{"key":"R37-20260113","doi-asserted-by":"crossref","first-page":"e005076","DOI":"10.1136\/rmdopen-2024-005076","article-title":"Efficacy of valaciclovir in preventing herpes zoster in patients receiving anifrolumab.","volume":"11","author":"Trefond","year":"2025","journal-title":"RMD Open"},{"key":"R38-20260113","doi-asserted-by":"crossref","first-page":"102981","DOI":"10.1016\/j.pmedr.2025.102981","article-title":"Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017\u2013April 2024.","volume":"50","author":"Shu","year":"2025","journal-title":"Prev Med Rep"},{"key":"R39-20260113","doi-asserted-by":"crossref","first-page":"996662","DOI":"10.3389\/fimmu.2022.996662","article-title":"Evaluation of anifrolumab safety in systemic lupus erythematosus: a meta-analysis and systematic review.","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"R40-20260113","doi-asserted-by":"crossref","first-page":"e000464","DOI":"10.1136\/lupus-2020-000464","article-title":"Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials.","volume":"8","author":"Tummala","year":"2021","journal-title":"Lupus Sci Med"},{"key":"R41-20260113","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R42-20260113","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus.","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R43-20260113","doi-asserted-by":"crossref","first-page":"e000252","DOI":"10.1136\/lupus-2017-000252","article-title":"Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers.","volume":"5","author":"Tummala","year":"2018","journal-title":"Lupus Sci Med"},{"key":"R44-20260113","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3899\/jrheum.2024-0053","article-title":"Anifrolumab in refractory systemic lupus erythematosus: a real-world, multicenter study.","volume":"51","author":"Tani","year":"2024","journal-title":"J Rheumatol"},{"key":"R45-20260113","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1093\/rheumatology\/kead568","article-title":"Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry.","volume":"63","author":"Miyazaki","year":"2024","journal-title":"Rheumatology (Oxford)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044960","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T20:01:03Z","timestamp":1768334463000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":45,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044960","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"2025-07-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}